Regulation of T cell-mediated immunity by tryptophan

Details Regulation of T cell-mediated immunity by tryptophan Regulation of T cell-mediated immunity by tryptophan

2007-01-09

2007-01-09

Wehbe, Anne M. (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093200, C424S093100, C435S320100, C435S325000, C435S455000

Reexamination Certificate

active

10112362

ABSTRACT:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby , decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes. Regulation can be further manipulated using cytokines such as macrophage colony stimulating factor, interferon gamma, alone or in combination with antigen or other cytokines.

REFERENCES:
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5244807 (1993-09-01), Murtfeldt et al.
patent: 5723325 (1998-03-01), Murtfeldt et al.
patent: 5874560 (1999-02-01), Kawakami et al.
patent: 6451840 (2002-09-01), Munn et al.
patent: 6482416 (2002-11-01), Munn et al.
patent: 2001/0001040 (2001-05-01), Munn et al.
patent: 0 385 385 (1990-09-01), None
patent: WO 93/01286 (1993-01-01), None
Takikawa et al. (1990) J. Immunol., vol. 145 (4), 1246-1250.
Kaufman et al. (1995) Annu. Rev. Immunol., vol. 13, 339-367.
Habara-Ohkubo et al. (1993) Infection and Immunity, vol. 61 (5), 1810-1813.
Alexander et al. “Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes.”Diabetes, vol. 51, Feb. 2002, pp. 356-365.
Barlett et al. “Introduction of Immunomodulatory genes into isolated pancreatic islets via biolistic particle bombardment.”Transplant Proc. Mar. 1998:30(2):452.
Berney et al., “Transplantation of islets of Langerhans: new developments.”Swiss Med Wkly2002; 132:671-680.
Giannoukakis et al. “Targeting Autoimmune Diabetes with Gene Therapy.”Diabetes, vol. 48, Nov. 1999, pp. 2107-2121.
Giannoukakis et al. “Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I.”Gene TherDec. 2000;7(23):2015-22.
Giannoukakis et al. “Infection of intact human islets by a lentiviral vector.”Gene TherSep. 1999;6(9):1545-51.
Giannoukakis et al. “Adenoviral Gene Transfer of the Interleukin-1 Receptor Antagonist Protein to Human Islets Prevents IL-1β-Induced β-Cell Impairment and Activation of Islet Cell Apoptosis in Vitro.” Diabetes, vol. 48, Sep. 199, pp. 17301736.
Habara-Ohkubo et al. “Establishment of an Antitoxoplasma State by Stable Expression of Mouse Indoleamine 2,3-Dioxygenase.”Infection and Immunity, May 1993, vol. 61, No. 5, pp. 1810-1813.
Kapturczak et al. “Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector.”Mol TherFeb. 2002;5(2):154-60.
Kenyon et al. “Islet transplantation; present and future perspectives.”Diabetes Metab RevDec. 1998;14(4)303-313.
Mellor et al. “Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses.” IDO and T Cell Responses. 2002, pp. 3771-3776.
Sigalla et al. “Adenovirus-mediated gene transfer into isolated mouse adult pancreatic islets: normal beta-cell function despite induction of an anti-adenovirus immune response.”Hum Gene TherSep. 1, 1997;8(13) 1625-1634.
Weber, et al. “Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function.”J Surg ResApr. 1997;69(1):23-32.
Agrawal et al., “Oligodeoxynucleoside phosphoroamidates and phosphorothioates as inhibitors of human immunodeficiency virus”,Proc. Natl. Acad. Sci. USA, 85:7079-7083 (1988).
Albertati-Giani et al., “Regulation of the Kynurenine Metabolic Pathway by Interferon -γ in Murine Cloned Macrophages and Microglial Cells”,J. Neurochem., 66(3):996-1004 (1996).
Albina et al., “Nitric Oxide Production is Required for Murine Resident Peritoneal Macrophages to Suppress Mitogen-Stimulated T Cell Proliferation”,J. Immunol., 147(1):144-148 (1991).
Askew et al., “Molecular Recognition with Convergent Functional Groups. 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components”,J. Am. Chem. Soc., 111:1082-1090 (1989).
Attwood et al., “The Role of Tryptophan Depletionin T Cell Suppression by Macrophages”,Immunology, 92(1):7, Abstract only (1997).
Aune et al., “Inhibition of Tumor Cell Growth by Interferon-γ Is Mediated by Two Distinct Mechanisms Dependent upon Oxygen Tension: Induction of Tryptophan Degradation and Depletion of Intracellular Nicotinamide Adenine Dinucleotide”,J. Clin. Invest., 84:863-875 (1989).
Azuma et al., “B70 antigen is a second ligand for CTLA-4 and CD28”,Nature, 366:76-79 (1993).
Baynes et al., “Lactoferrin and the Inflammatory Response”,Adv. Exp. Med. Biol., 357:133-141 (1994).
Begg et al., “Delayed Hematopoietic Development in Osteopetrotic (op/op) Mice”,J. Exp. Med., 177:237-242 (1993).
Belongia et al., “An Investigation of the Cause of the Eosinophilia-Myalgia Syndrome Associated with Tryptophan Use”,The New England Journal of Medicine, 323(6):357-365 (1990).
Bliznakov, “Serotonin and its precursors as modulators of the immunological responsiveness in mice”,Journal of Medicine, 11:81-105 (1980).
Blume et al., “Triple Helix Formation by Purine-rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter”,Nucl. Acids Res., 20:1777-1784 (1992).
Bock et al., eds., “Polyfunctional Cytokines: IL-6 and LIF”,Ciba Foundation Symposium 167, Title Page and Table of Contents (1992).
Bock et al., eds., “Interactions Among Cell Signaling Systems”,Ciba Foundation Symposium 164, Title Page and Table of Contents (1992).
Bogdan, “The Multiplex Function of Nitric Oxide in (Auto)immunity”,J. Exp. Med., 187(9):1361-1365 (1998).
Bonney et al., “Much IDO about pregnancy”,Nature Medicine, 4(10):1128-1129 (1998).
Brás et al., “Nitric Oxide Regulates Clonal Expansion and Activation-Induced Cell Death Triggered by Staphylococcal Enterotoxin B”,Infection and Immunity, 65(10):4030-4037 (1997).
Burke et al., “The role of indoleamine 2,3-dioxygenase in the anti-tumor activity of human interferon-gamma in vivo”,Int. J. Cancer, 60(1):115-122 (1995).
Cady et al., “1-Methyl-DL-tryptophan, β-(3-Benzofuranyl)-DL-alanine (the Oxygene Analog of Tryptophan), and β-[3-Benzo(b)thienyl]-DL-alanine (the sulfur Analog of Tryptophan) Are Competitive Inhibitors for Indoleamine 2,3-Dioxygenase”,Arch. Biochem. Biophys., 291(2):326-333 (1991).
Capecchi, Ed., “Molecular Genetics of Early Drosophila and Mouse Development”,Current Communications in Molecular Biology, Cold Spring Har

Affiliated with

Also associated with

Rating

Regulation of T cell-mediated immunity by tryptophan does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Regulation of T cell-mediated immunity by tryptophan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of T cell-mediated immunity by tryptophan will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3755422